 |
71 Diseases |  |
100 Trials |
|
100 Trials |  |
2706 News |  |
| «12...678910111213141516...3738» |
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Surgery: Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - May 11, 2022
P1b, N=16, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Aug 2022 --> Aug 2023
- | Halaven (eribulin mesylate) / Eisai, Adcetris (brentuximab vedotin) / Seagen, Takeda, Germanin (suramin) / Optimum Therap
Journal: Drug-Induced Peripheral Neuropathy: Diagnosis and Management. (Pubmed Central) - May 11, 2022
More than 30 causes of peripheral neuropathy exist ranging from systemic and auto-immune diseases, vitamin deficiencies, viral infections, diabetes, etc. One of the major causes of peripheral neuropathy is drug induced disease, which can be split into peripheral neuropathy caused by chemotherapy or by other medications. This review deals with the latest causes of drug induced peripheral neuropathy, the population involved, the findings on physical examination and various workups needed and how to manage each case.
- | Halaven (eribulin mesylate) / Eisai
Biomarker, Journal: Complete Response To Eribulin In A Patient With Unresectable Liposarcoma: A Case Report And Implications Of New Biomarkers. (Pubmed Central) - May 10, 2022
This result is consistent with our previous preclinical study that demonstrated the significance of p-AKT signaling for eribulin resistance in multiple subtypes of soft tissue sarcoma (STS) cells. This case highlights the potential benefits of eribulin as well as the mechanism underlying resistance to eribulin in patients with unresectable or metastatic STS, especially liposarcoma.
- || Imfinzi (durvalumab) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment open, Surgery: SOLARA: Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (clinicaltrials.gov) - May 10, 2022
P1/2, N=41, Recruiting, Sponsor: Colette Shen
This case highlights the potential benefits of eribulin as well as the mechanism underlying resistance to eribulin in patients with unresectable or metastatic STS, especially liposarcoma. Not yet recruiting --> Recruiting
- ||| Vonjo (pacritinib) / CTI BioPharma
P3 data, Journal: Co-treatment of Low Dose Pacritinib, a Phase III Jak2 Inhibitor, Greatly Increases Apoptosis of P-gp Over-expressing Cancer Cells With Multidrug Resistance. (Pubmed Central) - May 7, 2022
Collectively, pacritinib, induced G arrest, reduced cell viability, had high P-gp inhibitory activity, and upregulated the expression of pH2AX when used in combination with VIC. As pacritinib is a Jak2 inhibitor currently in phase III clinical trials, our findings may facilitate the application of this co-treatment in patients with MDR cancer.
- || Halaven (eribulin mesylate) / Eisai, eribulin liposomal (E7389-LF) / Eisai
P1 data, Clinical Trial,Phase I, Journal: Phase 1 Dose Escalation Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. (Pubmed Central) - May 6, 2022
Considering the toxicity profile of both regimens, the recommended dose was 2.0 mg/m Q3W. Expansion cohorts are ongoing.
- | Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Metastases: Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer (clinicaltrials.gov) - May 6, 2022
P2, N=64, Recruiting, Sponsor: Hunan Cancer Hospital
Expansion cohorts are ongoing. Trial completion date: Aug 2022 --> May 2022
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Votrient (pazopanib) / Novartis, Halaven (eribulin mesylate) / Eisai
Review, Journal: Long-term survival of an adult patient with undifferentiated embryonal sarcoma of the liver with multidisciplinary treatment: a case report and literature review. (Pubmed Central) - May 6, 2022
Trial completion date: Aug 2022 --> May 2022 Improved long-term survival was achieved in an adult patient with UESL after multidisciplinary therapy, involving a combination of three surgical procedures and several chemotherapies.
- |||| Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Trial completion date, Trial primary completion date, Metastases: TROPiCS-02: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (clinicaltrials.gov) - May 5, 2022
P3, N=543, Active, not recruiting, Sponsor: Gilead Sciences
Improved long-term survival was achieved in an adult patient with UESL after multidisciplinary therapy, involving a combination of three surgical procedures and several chemotherapies. Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Nov 2021 --> Oct 2024
- | Halaven (eribulin mesylate) / Eisai
Journal: Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation. (Pubmed Central) - May 1, 2022
Administration of the ERK1/2 inhibitor PD98059 increased the viability of TNBC cells treated with cisplatin plus eribulin. Conclusions; Eribulin could synergize the cytotoxic and apoptotic activities of cisplatin and increase ERK1/2 activation, thus enhancing anti-cancer effects against TNBC cells.
- | Halaven (eribulin mesylate) / Eisai
Journal, Real-world evidence: Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer (Pubmed Central) - Apr 29, 2022
The main adverse reactions in the whole group of patients were Grade Ⅲ-Ⅳ neutrophil decline [29.9% (23/77)], and other adverse reactions were Grade Ⅲ-Ⅳ fatigue [5.2% (4/77)], Grade Ⅲ-Ⅳ peripheral nerve abnormality [2.6% (2/77)] and Grade Ⅲ-Ⅳ alopecia [2.6% (2/77)]. Eribulin still has good antitumor activity against various molecular subtypes of breast cancer and advanced breast cancer that has failed multiple lines of chemotherapy, and the adverse effects can be controlled, so it has a good clinical application value.
- | Xalkori (crizotinib) / Pfizer, Halaven (eribulin mesylate) / Eisai, Tasigna (nilotinib) / Novartis, Inhibikase
Biomarker, Journal, IO biomarker: M2-Polarization-related CNTNAP1 gene might be a novel immunotherapeutic target and biomarker for clear cell renal cell carcinoma. (Pubmed Central) - Apr 28, 2022
Finally, high CNTNAP1 expression was negatively correlated with Nilotinib, Crizotinib, Eribulin mesylate, and Vinorelbine. Collectively, these results strongly suggest that CNTNAP1 might act as an immunotherapeutic target and a promising novel biomarker for ccRCC.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5887;
P1, P3
DESTINY-Breast04 is the first phase 3 trial of a HER2-directed therapy in pts with HER2-low mBC to show a statistically significant and clinically meaningful benefit in PFS and OS compared to standard-of-care treatment, regardless of HR status, with a generally manageable safety profile. Funding: Daiichi Sankyo, Inc., and AstraZeneca.
- farletuzumab ecteribulin (MORAb-202) / Eisai, BMS
Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial. (Available On Demand; 392) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5454;
P1
While pt numbers were small, efficacy was observed irrespective of FRα-expression levels. ILD/pneumonitis was the most common TEAE and was low grade in most pts.
- Halaven (eribulin mesylate) / Eisai, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. (Available On Demand; 100) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5145;
P1
Durable responses and disease control were observed with metastatic TNBC. Further study is needed to examine the determinants of response to this combination.
- farletuzumab ecteribulin (MORAb-202) / Eisai, BMS
Dose optimization for MORAb-202, an antibody-drug conjugate (ADC) highly selective for folate receptor-alpha (FRα), using population pharmacokinetic (PPK) and exposure-response (E-R) efficacy and safety analyses. (Available On Demand; 82) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5127;
P1
Background: MORAb-202 is an ADC consisting of farletuzumab (an antibody that binds to FRα) paired with eribulin mesylate (a microtubule dynamics inhibitor) conjugated via a cathepsin B-cleavable linker. Based on this assessment, BSA-based dosing is predicted to lower the exposure-dependent ILD risk in patients with higher BW and is being further evaluated in ongoing clinical studies.
- Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
Real-world data comparing third and subsequent line regimens for treatment of metastatic triple-negative breast cancer in the United States. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4824;
We identified 210 (52%) individuals with mTNBC who received Eribulin (E) for 3L+, compared to 189 patients treated with other chemotherapies (O), which include carboplatin+gemcitabine, nab-paclitaxel, vinorelbine, paclitaxel, carboplatin and nab-paclitaxel+atezolizumab, ordered by frequency. Our analysis of real-world oncology data aligns with National Institute for Health and Care Excellence (NICE) recent recommendation in showing no survival benefit or reduction in post-treatment adverse events when treating with Eribulin at 3L+ in metastatic TNBC patients.
- Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma. (Available On Demand; 374) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4391;
This phase II study met its primary endpoint of 1yOS%, although no obvious response was observed. Further investigation to reveal the biomarkers related to longer survival is underway.
- Halaven (eribulin mesylate) / Eisai
Efficacy and safety of eribulin in the treatment of advanced adult soft tissue sarcoma (STS): First real-world data in Chinese population. (Available On Demand; 481) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3149;
Eribulin monotherapy or combination therapy were likely more effective in this population, as well-tolerated as with Study 309, especially in treating liposarcoma. Eribulin used in combination with TKI and anti-PD-1 antibody showed potential efficacy in STSs.
- Halaven (eribulin mesylate) / Eisai
A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3077;
P1/2
L at 14mg (vs 18mg) had a better AE profile without compromising activity. Future randomized study to confirm the efficacy of the combination is warranted.
- Halaven (eribulin mesylate) / Eisai
A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937. (Available On Demand; 94a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2538;
P3
Erdafitinib is approved for pts with FGFR alterations and Enfortumab vedotin (EV) is approved for previously treated pts...Pts with liver metastases benefited from therapy with 5 responders in 7 pts for GE vs 12 out 49 E. This is a phase III, randomized 3 arm study comparing E vs. GE vs. SOC (docetaxel, paclitaxel, or gemcitabine)...We require 140 eligible (155 total) pts in each arm for a total of 465. The study was activated in Feb 2021 and accrual is ongoing.
- Halaven (eribulin mesylate) / Eisai
Survival outcomes in patients with metastatic breast cancer treated with eribulin: A real-world evidence study from India. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1267;
This real-world retrospective study supports and confirms the efficacy of eribulin in Indian patients with MBC (heavily pre-treated). It should be considered in the strategy of several chemotherapy lines in MBC.
- Halaven (eribulin mesylate) / Eisai
Effectiveness and safety of eribulin as a front-line treatment in advanced breast cancer patients in China: A prospective real-world study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1264;
P
Eribulin monotherapy or combined with targeted therapy was effective and well-tolerated as the first to third lines of treatment in ABC. This promising therapeutic outcome might warrant further studies in early eribulin administration in ABC patients.
- Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1249;
P2
The combination of eribulin and anlotinib showed a better treatment response and tolerable toxicity in HER2-negative metastatic breast cancer patients. Further studies enrolling more patients are still needed.
- Halaven (eribulin mesylate) / Eisai
HERibuline: Eribulin mesylate and Trastuzumab in pretreated HER2-positive advanced breast cancer—A report of region’s practice. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1223;
However, in pretreated and advanced metastatic setting, there are few scientific evidence to guide the choice of treatments. A combination of E/T could be an effective option in patients with good performance status and willing to receive treatment.
- Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC). (Available On Demand; 494b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1214;
P1/2
A sample size of 88 achieves 80% power to detect PFS difference of median PFS 6.95 vs 4 months (corresponding to a hazard ratio of 0.5755) between the 2 arms, based on 1-sided two-sample log rank test at 0.1 α level. The phase I study is actively enrolling pts.
- Halaven (eribulin mesylate) / Eisai, Opdivo (nivolumab) / Ono Pharma, BMS
A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16). (Available On Demand; 475) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1184;
P1/2
In this parallel phase II clinical trial, the addition of nivolumab to eribulin showed promising efficacy and tolerable safety profile in previously treated HER2- MBC. Further survival and exploratory analyses to find predictive markers will be followed.
- Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Eribulin mesylate versus eribulin plus anlotinib in patients with advanced or metastatic breast cancer: Results of a phase II study. (Available On Demand; 471) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1180;
P2
Further survival and exploratory analyses to find predictive markers will be followed. Eribulin plus anlotinib was associated with a significantly better DCR, ORR and PFS than eribulin monotherapy in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
- Halaven (eribulin mesylate) / Eisai
Real-world treatment patterns and outcomes among patients (pts) with second-line (2L) and third-line (3L) metastatic triple-negative breast cancer (mTNBC) in England using the Cancer Analysis System (CAS). (Available On Demand; 453) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1162;
This nationwide study, in England, accentuates the significant unmet need in 2L and 3L therapy for mTNBC highlighted by the poor prognosis. The stratification by prior treatment-free interval from curative setting did not show a difference in OS or PFS for patients receiving 2L treatment.
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. (Available On Demand; 449) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1158;
P3
The analysis based on the final database lock of ASCENT confirms the superior survival outcomes of SG over single-agent chemotherapy, with a manageable safety profile and improvement in QoL for pts with mTNBC in the 2L+ setting. These findings reinforce SG as an effective treatment option for this pt population.
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1085;
P3
Pts were randomized 1:1 to receive SG (10 mg/kg IV on d1 and 8, every 21d) or TPC (capecitabine, eribulin, vinorelbine, or gemcitabine) until disease progression/unacceptable toxicity. SG had a statistically significant, clinically meaningful PFS benefit over single-agent chemotherapy and a manageable safety profile in pts with heavily pre-treated HR+/HER2– endocrine-resistant, unresectable locally advanced or MBC, who have limited treatment options.
- | Halaven (eribulin mesylate) / Eisai
Journal, BRCA Biomarker: Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. (Pubmed Central) - Apr 26, 2022
Intratumoral and stromal CD4 T cell density was an independent predictor of pCR in patients with TNBC. A larger study is warranted to confirm the results.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P3 trial, Metastases: Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab (clinicaltrials.gov) - Apr 25, 2022
P3, N=240, Recruiting, Sponsor: Fudan University
- | sacituzumab tirumotecan (MK-2870) / Merck (MSD)
New P3 trial, Metastases: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov) - Apr 25, 2022
P3, N=254, Not yet recruiting, Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Trial suspension, Combination therapy, Metastases: Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Apr 25, 2022
P1/2, N=18, Suspended, Sponsor: National Cancer Institute (NCI)
A larger study is warranted to confirm the results. Recruiting --> Suspended
- || Halaven (eribulin mesylate) / Eisai
Review, Journal: Efficacy of Eribulin in Soft Tissue Sarcomas. (Pubmed Central) - Apr 22, 2022
From retrospective studies, eribulin has demonstrated efficacy in patients with angiosarcoma, pleomorphic sarcomas, synovial sarcomas, rhabdomyosarcomas, angiosarcomas, and myxofibrosarcomas. Future areas of development include liposomal eribulin, which may provide increased efficacy and lower toxicity, and delineation of biomarkers of response and resistance, allowing better selection of patients for treatment.
- Halaven (eribulin mesylate) / Eisai, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Identifying Tumors with Defects in DNA Damage Response, Homologous Recombination, and Replication Stress (RM 1(Vista 1+2)) - Apr 22, 2022 - Abstract #GBCC2022GBCC_168;
Currently, various assays have been developed to try to better define tumors with HRD.We conducted a phase I/II trial of eribulin and olaparib for metastatic triple-negative breast cancer. The exploratory analysis of this study revealed that HRR-related gene mutations and high methylation levels are predictive factors for longer PFS in study treatment.In this symposium, I will summarize the identification methods of HRD such as HRD score, mutational signature, methylation abnormalities, HRDetect, and RAD51 score.
- ||| paclitaxel trevatide (ANG1005) / Angiochem
Trial completion date, Trial primary completion date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - Apr 22, 2022
P3, N=150, Not yet recruiting, Sponsor: Angiochem Inc
The exploratory analysis of this study revealed that HRR-related gene mutations and high methylation levels are predictive factors for longer PFS in study treatment.In this symposium, I will summarize the identification methods of HRD such as HRD score, mutational signature, methylation abnormalities, HRDetect, and RAD51 score. Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Apr 20, 2022
P2, N=100, Recruiting, Sponsor: Fudan University
Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Mar 2024 Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
- | Epidaza (chidamide) / Chipscreen
New P1/2 trial, Metastases: Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure (clinicaltrials.gov) - Apr 19, 2022
P1/2, N=102, Not yet recruiting, Sponsor: Henan Cancer Hospital
- || Halaven (eribulin mesylate) / Eisai, doxorubicin hydrochloride / Generic mfg., gemcitabine / Generic mfg.
2-5 lines of prior Rx. ~70% had metastatic disease. PFS primary end point. CrCL > 30, ECOG <2, good hepatic and marrow fx. Stratification also done based on receipt of #eribulin and #trabectidin. #doxorubicin (~90%) #gemcitabine (~40%), #CDK4inhibitor (~20%) other major players. (Twitter) - Apr 13, 2022
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Journal: Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma. (Pubmed Central) - Apr 12, 2022
In addition, age ≥40 (HR=0.23, 95% CI=0.10-0.52; p<0.001) was an independent predictor of longer PFS. Changes in NLR and age ≥40 years were able to predict the efficacy of trabectedin for STS.
- | Halaven (eribulin mesylate) / Eisai
Journal: Absolute Lymphocyte Count, Platelet-to-Lymphocyte Ratio, and Overall Survival in Eribulin-treated HER2-negative Metastatic Breast Cancer Patients. (Pubmed Central) - Apr 12, 2022
However, univariate analysis showed ALC (p=0.044) and PLR (p=0.044) to be significantly associated with OS. ALC and PLR can predict eribulin efficacy in terms of OS, reflecting the antitumour immune response in the microenvironment and indicating eribulin's effectiveness.
- ||| Halaven (eribulin mesylate) / Eisai, rebastinib (DCC-2036) / Deciphera
Trial termination, Metastases: Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (clinicaltrials.gov) - Apr 4, 2022
P1, N=28, Terminated, Sponsor: Montefiore Medical Center
ALC and PLR can predict eribulin efficacy in terms of OS, reflecting the antitumour immune response in the microenvironment and indicating eribulin's effectiveness. Recruiting --> Terminated; Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are terminating early.
- || farletuzumab (MORAB-003) / Eisai, Halaven (eribulin mesylate) / Eisai, eribulin/farletuzumab ADC (MORAb-202) / Eisai, BMS
Clinical, P1 data, Journal: First-in-human Phase 1 Study of MORAb-202, An Antibody-drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-positive Advanced Solid Tumors. (Pubmed Central) - Apr 1, 2022
P1
MORAb-202 demonstrated promising antitumor activity in FRα-positive solid tumors and was generally well-tolerated at the tested doses. Further investigations are required to establish appropriate dosage and clinical utility of MORAb-202.
- | fulvestrant / Generic mfg.
Journal: Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors. (Pubmed Central) - Apr 1, 2022
The major chemotherapy regimen in group C was eribulin (25%)...There was no difference in the incidence of grade 3 AEs between groups A and C or in the frequency of treatment discontinuation because of AEs among the 3 groups. Our study shows that mTOR inhibitors might be an effective treatment option for patients with HR+ HER2- MBC previously treated with CDK4/6 inhibitors.
- || Halaven (eribulin mesylate) / Eisai
Trial completion: Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) (clinicaltrials.gov) - Mar 31, 2022
P2, N=23, Completed, Sponsor: Eisai Inc.
Our study shows that mTOR inhibitors might be an effective treatment option for patients with HR+ HER2- MBC previously treated with CDK4/6 inhibitors. Active, not recruiting --> Completed
- || ipatasertib (RG7440) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: PATHFINDER: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Mar 31, 2022
P2a, N=54, Recruiting, Sponsor: MedSIR
Active, not recruiting --> Completed Trial completion date: Mar 2023 --> Jan 2024 | Trial primary completion date: Mar 2022 --> Nov 2022
- | Halaven (eribulin mesylate) / Eisai
New trial, Metastases: HERMIONE-10: Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer (clinicaltrials.gov) - Mar 31, 2022
P=N/A, N=200, Recruiting, Sponsor: University of Milano Bicocca
- | vinorelbine tartrate / Generic mfg., paclitaxel / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Paclitaxel induces micronucleation and activates pro-inflammatory cGAS-STING signaling in triple-negative breast cancer. (Pubmed Central) - Mar 26, 2022
Our study identifies a mechanism by which microtubule-targeting agents can potentiate an immune response in TNBC. Further, baseline cGAS expression may predict patient treatment response to therapies combining microtubule-targeting agents and immune checkpoint inhibitors.